Urokinase
From Proteopedia
(Difference between revisions)
| Line 27: | Line 27: | ||
**[[4fu7]], [[4fu8]], [[4fu9]], [[4fub]], [[5xg4]] - hUK + inhibitor<br /> | **[[4fu7]], [[4fu8]], [[4fu9]], [[4fub]], [[5xg4]] - hUK + inhibitor<br /> | ||
**[[1fv9]] – hUK (mutant) + benzimidazole derivative <br /> | **[[1fv9]] – hUK (mutant) + benzimidazole derivative <br /> | ||
| - | **[[ | + | **[[5yc6]], [[5yc7]] - hUK (mutant) + benzylamine derivative<br /> |
**[[1f5k]] - hUK (mutant) + benzamidine derivative<br /> | **[[1f5k]] - hUK (mutant) + benzamidine derivative<br /> | ||
**[[1f5l]] - hUK (mutant) + amiloride derivative<br /> | **[[1f5l]] - hUK (mutant) + amiloride derivative<br /> | ||
Revision as of 12:20, 3 October 2018
| |||||||||||
3D Structures of urokinase
Updated on 03-October-2018
References
- ↑ Carriero MV, Stoppelli MP. The urokinase-type plasminogen activator and the generation of inhibitors of urokinase activity and signaling. Curr Pharm Des. 2011;17(19):1944-61. PMID:21711235
- ↑ Han B, Nakamura M, Mori I, Nakamura Y, Kakudo K. Urokinase-type plasminogen activator system and breast cancer (Review). Oncol Rep. 2005 Jul;14(1):105-12. PMID:15944776
- ↑ West CW, Adler M, Arnaiz D, Chen D, Chu K, Gualtieri G, Ho E, Huwe C, Light D, Phillips G, Pulk R, Sukovich D, Whitlow M, Yuan S, Bryant J. Identification of orally bioavailable, non-amidine inhibitors of Urokinase Plasminogen Activator (uPA). Bioorg Med Chem Lett. 2009 Oct 1;19(19):5712-5. Epub 2009 Aug 7. PMID:19703768 doi:10.1016/j.bmcl.2009.08.008
